Months after $10M Series A, rare disease AI upstart Healx hauls in $56M in fresh funding
In 2010, Nick Sireau quit his job to focus solely on the patient group he had set up to help his sons diagnosed with a rare genetic disease called alkaptonuria (AKU). Researchers had found a feasible treatment from an unlikely source: a weedkiller, but it was being used to help infants with a different disorder. Sireau would then confront the perils of the traditional trial-and-error drug discovery process that demands time and money.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
